trending Market Intelligence /marketintelligence/en/news-insights/trending/SCAG7NFlpnAq_6r3u976vg2 content esgSubNav
In This List

EMA accepts The Medicines Co.'s application for urinary tract infection drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


EMA accepts The Medicines Co.'s application for urinary tract infection drug

The European Medicines Agency acknowledged receipt of The Medicines Company's application for Vabomere to treat complicated urinary tract infections.

The application is backed by data from phase 3 trial. Vabomere was previously known as Carbavance.